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Genomic disorders are a group of human genetic dis-
eases caused by genomic rearrangements resulting
in copy-number variation (CNV) affecting a dosage-
sensitive gene or genes critical for normal develop-
ment or maintenance. These disorders represent a
wide range of clinically distinct entities but include
many diseases affecting nervous system function.
Herein, we review selected neurodevelopmental, neu-
rodegenerative,andpsychiatricdisorderseitherknown
or suggested to be caused by genomic rearrangement
and CNV. Further, we emphasize the cause-and-effect
relationship between gene CNV and complex disease
traits. We also discuss the prevalence and heritability
of CNV, the correlation between CNV and higher-order
genomearchitecture, and theheritabilityofpersonality,
behavioral, and psychiatric traits. We speculate that
CNV could underlie a significant proportion of normal
human variation including differences in cognitive,
behavioral, and psychological features.
Introduction
Fifteen years ago, it became evident that genomic rear-
rangements and gene dosage effects, rather than the
classical model of coding region DNA sequence alter-
ations, could be responsible for a common, autosomal
dominant, adult-onset neurodegenerative trait—Char-
cot-Marie-Tooth neuropathy type 1A (CMT1A; Lupski
et al., 1991; Raeymaekers et al., 1991; Lupski et al.,
1992). With the identification of the CMT1A duplication
and its reciprocal deletion causing hereditary neuropa-
thy with liability to pressure palsies (HNPP), the demon-
stration that PMP22 copy-number variation (CNV) could
cause inherited disease in the absence of coding-
sequence alterations, was initially hard to fathom. How
could such subtle changes—three copies of the normal
‘‘wild-type’’ PMP22 gene rather than the usual two—
underlie neurologic disease?
Nevertheless, it has become apparent during this last
decade and a half that neurodegeneration can represent
the outcome of subtle mutations acting over prolonged
time periods in tissues that do not generally regenerate,
regardless of exact molecular mechanism. This concept
has revealed itself through (1) conformational changes
causing prion disease, (2) the inability to degrade accu-
mulated toxic proteins in amyloidopathies, a-synuclei-
nopathies, and polyglutamine expansion disorders, and
(3) alteration in gene copy number and/or expression
level through mechanisms such as uniparental disomy
(UPD), chromosomal aberrations (e.g., translocations),
*Correspondence: jlupski@bcm.tmc.eduand submicroscopic genomic rearrangements including
duplications, deletions, and inversions.
Currently, structural variation of the human genome is
commanding a great deal of attention (Feuk et al., 2006;
Freeman et al., 2006). In the postgenomic era, the avail-
ability of human genome sequence for genome-wide
analysis has revealed higher-order architectural fea-
tures (i.e., beyond primary sequence information) that
may cause genomic instability and susceptibility to
genomic rearrangements. Nevertheless, it is perhaps
less generally appreciated that any two humans contain
more base-pair differences due to structural variation
of the genome than resulting from single-nucleotide
polymorphisms (SNPs; Rendon et al., 2006). De novo
genomic rearrangements have been shown to cause
both chromosomal and Mendelian disease, as well as
sporadic traits (Lupski, 2006; Lupski and Stankiewicz,
2006), but our understanding of the extent to which
genomic rearrangements, gene CNV, and/or gene dos-
age alterations are responsible for common and com-
plex neurological traits remains rudimentary.
Interestingly, several neurodegenerative and neuro-
developmental disorders are now known to be caused
by disparate recurrent and nonrecurrent genomic rear-
rangements that are mediated or stimulated by complex
regional genomic architecture occurring throughout the
human genome. These genomic disorders include pe-
ripheral (PNS) and central (CNS) nervous system neu-
ropathies, well-recognized syndromes with characteris-
tic behavioral or neurocognitive phenotypes, and also
a growing number of psychiatric illnesses. Thus, there
is indisputable evidence that CNV can play a role in the
pathogenesis of neurodevelopmental and neurodegen-
erative disorders. In this review, we will discuss the
mechanisms of genomic rearrangements and CNV,
then focus on selected disorders that involve neurode-
velopmental, neurodegenerative, and psychiatric symp-
toms in greater detail. In addition, we will discuss the
role of CNV in normal human variation and hypothesize
that genomic rearrangements may underlie not only
neurologic diseases, but also complex traits. Finally,
we speculate that gene CNV due to structural alteration
may be responsible for both normal and abnormal
behavioral phenotypes.
Mechanisms of Genomic Rearrangements
Genomic rearrangements include duplications, dele-
tions, and inversions of unique genomic segments at
specific regions, as well as translocations, marker chro-
mosomes, isochromosomes, and other complex rear-
rangements (Lupski, 1998; Emanuel and Shaikh, 2001;
Stankiewicz and Lupski, 2002). These rearrangements
are not random events but instead reflect the involve-
ment of higher-order architectural features of the human
genome.
The architectural features that appear to render
genomic regions susceptible to rearrangement include
region-specific repeat sequences, or low-copy repeats
(LCRs). LCRs can contain one or multiple genes, pseu-
dogenes, gene fragments, retroviral sequences,
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104regulatory regions, or other paralogous segments (Lup-
ski, 1998) and are characterized as repeat sequences,
as opposed to highly repetitive sequences (i.e., long or
short interspersed elements, retrotransposons, satellite
DNA, centromeres (Lee et al., 1997), and telomeres) that
were initially identified on the basis of reassociation ki-
netics (Britten and Davidson, 1976). LCRs are often
found in pericentromeric and subtelomeric regions of
human chromosomes (Eichler et al., 1999), but they
may be found in interstitial regions as well. LCRs are
sometimes referred to as segmental duplications or du-
plicons (Bailey et al., 2001), although the latter term can
be ambiguous when greater than two copies of the re-
peated segment exist. The size, relative orientation, dis-
tance between copies, and shared percent identities of
the LCRs are factors that render the genomic region sus-
ceptible to rearrangement and may influence the type of
rearrangement which occurs.
Rearrangements are classified as either recurrent or
nonrecurrent, depending on whether the same rear-
rangement can be identified in unrelated individuals, and
can be either constitutional (germline) meiotic events or
de novo somatic events confined to a subset of cells
(Shaffer and Lupski, 2000). In general, recurrent rear-
rangements, or those of common size and having clus-
tered breakpoints, most frequently result from a mecha-
nism of nonallelic homologous recombination (NAHR)
between region-specific LCRs (Lupski, 1998; Stankie-
wicz and Lupski, 2002; Figure 1). In general, genomic
architectural features favorable for rearrangements to
occur via NAHR and cause gene CNVs consist of LCRs
(1) >10 kb in size, (2) with >97% sequence identity, (3)
directly oriented, (4) within 5 Mb of each other, and (5)
located on the same chromosome (i.e., intrachromoso-
mal; Lupski, 1998). Establishing a mechanism for these
rearrangements and delineating the ‘‘rules’’ governing
their occurrence enables an informed approach for de-
signing targeted assays interrogating such regions of
predicted genomic instability (Stankiewicz and Lupski,
2002; Sharp et al., 2006). Nonrecurrent rearrangements,
or those for which breakpoints do not cluster and that
are generally different in size between families, can re-
sult from either NAHR or nonhomologous end-joining
(NHEJ) mechanisms (Inoue et al., 2002; Shaw and Lup-
ski, 2005). Whereas LCRs have been shown to mediate
recurrent and nonrecurrent recombinational repair by
NAHR, it is postulated that LCRs may instead stimulate,
but not necessarily mediate, nonrecurrent recombina-
tional repair by the error-prone mechanism of NHEJ
(Inoue et al., 2002; Stankiewicz et al., 2003; Shaw and
Lupski, 2005; Lee et al., 2006a). However, the precise
mechanism by which this stimulation may occur remains
to be elucidated.
Neurodevelopmental Disorders
Neurodevelopmental disorders are generally character-
ized by neurological signs which occur during a stage
of rapid nervous system development—from the point
of conception to early adulthood. These disorders en-
compass a variety of signs and symptoms including
a range of cognitive impairment from learning disability
to mental retardation, abnormal behaviors, sensory im-
pairment, seizures, and/or neuromotor dysfunction.
Neurodevelopmental disorders can be either genetic(metabolic, chromosomal, or structural) or acquired.
Herein, we will focus on several neurodevelopmental
disorders caused by genomic rearrangement and CNV
(Table 1).
Williams-Beuren Syndrome and Its Reciprocal
Duplication
It is likely that specific genes contained within chromo-
some 7q11.23 are dosage sensitive and play a role in
human language and visuospatial proficiency. A recur-
rent microdeletion of w1.6 Mb results in CNV of 28
genes, causing Williams-Beuren syndrome (WBS; OMIM
#194050). Interestingly, the expression levels of genes
flanking but not included in the deletion in WBS patients
also have been found to be reduced (Merla et al., 2006),
suggesting a potential dosage-sensitive role of genes
adjacent to the commonly deleted region that may con-
tribute to or modify other aspects of the WBS pheno-
type. The reciprocal duplication of the same region,
which was only recently reported (Somerville et al.,
2005), causes a clinically distinct disorder dominated by
speech delay.
Individuals with WBS exhibit a combination of striking
behavioral abnormalities and a characteristic neurocog-
nitive profile. WBS patients present with a distinctive
Figure 1. General Scheme for Nonallelic Homologous Recombina-
tion (NAHR) between LCRs
(A) Duplications and deletions are generated when NAHR is medi-
ated by directly oriented LCRs.
(B) Inversions are generated when NAHR is mediated by inversely
oriented LCRs.
(C) Different complex rearrangements are generated depending on
the combination of LCRs that participate in the NAHR event. Colored
arrows represent LCRs. Recombination is signified by ‘‘X.’’ Gradi-
ently shaded arrow represents a unique directional segment of
DNA, and an example of CNV of a unique segment (i.e., gene) is
shown in the products of (A).
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105Table 1. Neurodevelopmental Disorders Caused by Genomic Rearrangements and Gene Copy-Number Variation
Syndrome OMIM Locus Rearrangement
Size
(Mb) Repeats Mech. Gene(s) Neurologic Findings
WBS
del(7)q11.23
#194050 7q11.23 del 1.6 A, B, C
blocks
NAHR CGS, incl.
ELN
Difficult coordination,
hyperreflexia, nystagmus,
CNS structural changes,
anxiety, ADHD, MR, loquacious
dup(7)q11.23 7q11.23 dup 1.6 A, B, C
blocks
NAHR CGS, incl.
ELN
Speech/language delay,
MR, growth retardation
AS #105830 15q11–q13 mat del, pat
UPD15
4 END
repeats
NAHR UBE3A Ataxia, autistic
features, MR, hyperactivity,
absent speech, seizure
PWS #176270 15q11–q13 pat del, mat
UPD15
4 END
repeats
NAHR CGS Hypotonia, motor
abnormalities, learning
disability, OCD
idic(15) idic(15)(q12)
or
idic(15)(q13)
trip LCR15s U-type
exchange
CGS Ataxia, autistic features,
hypotonia, abnormal EEG,
epilepsy, PDD, MR, language
delay, stereotypic behavior
dup(15) 15q11–q13 dup LCR15s NAHR CGS Autistic features,
hypotonia, limb apraxia,
MR, language disorder
MDLS #247200 17p13.3 del R1.3 CGS incl.
LIS1
Brain malformation
lissencephaly, MR,
epilepsy, spasticity
SMS #182290 17p11.2 del 3.7 SMS-REPs,
Alu
NAHR,
NHEJ
CGS incl.
RAI1
Delayed gross
motor skills, MR, hypotonia,
abnormal EEG, seizure,
stereotypic behaviors
dup(17)p11.2 17p11.2 dup 3.7 SMS-REPs NAHR RAI1 Hypotonia, autistic
features, poor
balance, ADHD, mild MR
NF1 +162200 17q11.2 del 1.5, 1.2 NF1-REPs,
JJAZ,
JJAZ-J
NAHR CGS, incl.
NF1
Neurofibromas, CNS tumors,
difficult coordination/memory,
seizure, MR, ADHD,
abnormal MRI
del(22)q11.2 #188400/
#192430
22q11.2 del 3 LCR22s;
Alu
NAHR CGS incl.
TBX1,
COMT
Seizure, cerebellar
atrophy, language/speech
deficit, ADHD, anxiety,
psychiatric phenotype
dup(22)q11.2 #608363 22q11.2 dup 3–6 LCR22s NAHR CGS Motor delays,
cognitive deficits, aggression/
depression/anxiety, ADHD
del(22)q13 #606232 22q13.3 del 0.1–9 SHANK3/
PROSAP2
Hypotonia, delayed/absent
speech, MR, autistic features
RTT #312750 Xq28 del 0.15–
0.08
LCR-MECP2s MECP2 Stereotypic behavior, ataxia,
cognitive impairment,
autism, spastic paraparesis,
epilepsy
Rett-like
syndrome
Xq28 dup, trip 0.2–2.2 LCR-MECP2s MECP2 Hypotonia, spasticity, MR,
absent language/speech,
stereotypic behaviors
PMD #312080 Xq22.2 dup 0.4–7+ LCR-PMDs NHEJ PLP1 Nystagmus, spastic quadriplegia,
ataxia, dysarthria, abnormal MRI,
mild MR, CNS dysmyelination,
choreoathetotic movements
Xq22.2 del 0.2–0.75 LCR-PMDs;
Alu
NHEJ PLP1 PNS and CNS neuropathy,
CNS demyelination, mild
distal sensory loss,
hyporeflexia, abnormal MRI
dup(X)q26.2-
q27.1
Xq26.2–
q27.1
dup 7.5 CGS, incl.
SOX3
Seizure, nystagmus, speech
disorder
mech, mechanism; mat, maternal; pat, paternal; dup, duplication; del, deletion; trip, triplication; UPD, uniparental disomy; CNS, central nervous
system; PNS, peripheral nervous system; ADHD, attention-deficit hyperactivity disorder; MR, mental retardation; OCD, obsessive-compulsive
disorder; PDD, pervasive developmental disorder; MRI, magnetic resonance imaging; EEG, electroencephalogram; OMIM, http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=OMIM.facial phenotype, a spectrum of learning disability
and/or mental retardation, prominently featuring severe
visuospatial construction deficits, and attention-deficit
hyperactivity disorder (ADHD; Mervis et al., 2000; Morriset al., 2003; Leyfer et al., 2006). Patients with WBS tend
to have neurologic and sensorineural difficulties such as
hyperacusis (Chapman et al., 1996; Marler et al., 2005) in
addition to CNS structural abnormalities (Jernigan and
Neuron
106Bellugi, 1990; Pober and Filiano, 1995; Mercuri et al.,
1997; Schmitt et al., 2001; Galaburda et al., 2002; Tom-
aiuolo et al., 2002). Their behavior is described as outgo-
ing and loquacious with high-level verbal abilities that
can make their mental capabilities appear greater than
shown by formal IQ testing. Conversely, the phenotype
seen in a small number of individuals reported to have
the reciprocal duplication includes a severe delay in ex-
pressive speech and language, developmental delay,
growth retardation, mental retardation, and a behavioral
phenotype (J. Berg et al., personal communication;
Somerville et al., 2005; Kriek et al., 2006).
The WBS deletion, and presumably the reciprocal du-
plication, is caused by meiotic NAHR (Urban et al., 1996)
mediated by highly homologous flanking LCR structures
(Peoples et al., 2000; Baye´s et al., 2003). Inversion of the
same segment has been found as a polymorphic variant
in 33% of the parents of WBS patients, in some atypical
WBS patients (27%), and also in some individuals with
mental retardation and features associated with WBS
(Osborne et al., 2001). Interestingly, inversion polymor-
phisms at this and other loci appear to be associated
with susceptibility to germline deletion (Osborne et al.,
2001; Giglio et al., 2002; Gimelli et al., 2003; Koolen
et al., 2006; Lupski, 2006; Sharp et al., 2006; Shaw-Smith
et al., 2006).
15q11–q13 Rearrangements in Angelman and
Prader-Willi Syndromes, idic(15), and dup(15)
The 15q11–q13 region has been shown to undergo geno-
mic rearrangement at a relatively high frequency. A re-
currentw4 Mb deletion of this region is responsible for
most cases of Angelman (AS; OMIM #105830; Williams
et al., 1995) and Prader-Willi (PWS; OMIM #176270; Bittel
and Butler, 2005) syndromes, depending on the parent of
origin for the deletion. Whereas AS patients have more
severe cognitive and neurological impairment and sei-
zures, PWS patients have more severe behavioral and
endocrine abnormalities (Cassidy et al., 2000). The
distinction between these phenotypes is related to im-
printing effects (Jiang et al., 1998). In rare cases, the AS
phenotype is caused by mutations in the maternally ex-
pressed UBE3A (E6-AP ubiquitin protein ligase) gene
(Kishino et al., 1997), while no single-gene mutations
have been shown to be responsible for the PWS pheno-
type.
Presumably LCRs flanking the AS/PWS region (i.e.,
partially duplicated paralogs of the HERC2 gene, END
repeats) are thought to mediate the rearrangements
seen in AS/PWS patients (Amos-Landgraf et al., 1999).
Additionally, END repeats and LCR15s (Pujana et al.,
2002) also mediate formation of isodicentric chromo-
some 15s or idic(15) (Robinson et al., 1993; Battaglia,
2005), also formerly known as inverted duplication 15,
and 15q11–q13 interstitial duplication rearrangements
or dup(15) (Browne et al., 1997; Repetto et al., 1998).
The clinical outcomes of these syndromes are depen-
dent on (1) the inclusion of the AS/PWS w4 Mb critical
region in the rearranged segment, (2) parent of origin
for the rearrangement, and (3) in the case of idic(15),
the ploidy of the isodicentric chromosome. It is evident
that the AS/PWS critical region contains genes impor-
tant for development, cognition, speech and language,
behavior, and other neurological functions, and that
the chromosome 15q11–q13 region is highly unstableand susceptible to LCR-mediated genomic rearrange-
ment and CNV-causing disease.
Miller-Dieker Syndrome and Lissencephaly
Miller-Dieker syndrome (MDLS; OMIM # 247200) is
a neurodevelopmental disorder mediated by microdele-
tion of 17p13.3, and is a contiguous gene syndrome
(CGS) including the LIS1 (lissencephaly-1) gene (Dobyns
et al., 1993). CGSs are a group of clinically recognizable
disorders characterized by duplication or deletion of
a chromosomal interval spanning multiple contributory
genes (Shaffer et al., 2001). MDLS is characterized by
the brain malformation lissencephaly (LIS), dysmorphic
facial features, mental retardation, epilepsy, spasticity,
and reduced longevity (Dobyns et al., 1993). A milder
form without dysmorphic facial features and with
a less-severe grade of LIS is considered as isolated lis-
sencephaly sequence (ILS). Compared to patients with
ILS, those with MDLS have larger deletion intervals
(R1.3 Mb) and show a more severe grade of LIS, likely
due to the inclusion of particular genes other than LIS1
in the deletion interval (Cardoso et al., 2003). Although
a complete in silico analysis for LCRs in this region has
not been formally documented, candidate LCRs which
may cause susceptibility and genomic instability result-
ing in these nonrecurrent rearrangements are present
(UCSC Genome Browser, http://genome.ucsc.edu/).
Smith-Magenis Syndrome and Its Reciprocal
Duplication
Smith-Magenis syndrome (SMS; OMIM #182290) is
a CGS caused most frequently by recurrent microdele-
tions of 3.7 Mb on 17p11.2 and less frequently by nonre-
current (atypical) deletions (Greenberg et al., 1991; Chen
et al., 1997; Shaw et al., 2004b; Shaw and Lupski, 2005;
Bi and Lupski, 2006). SMS is characterized by specific
neurobehavioral anomalies, sleep disturbance, cranio-
facial anomalies, and brachydactyly in addition to devel-
opmental delay and variable mental retardation (Green-
berg et al., 1991, 1996; Finucane et al., 1994; Chen et al.,
1996; Dykens and Smith, 1998; Bi and Lupski, 2006;
Goldman et al., 2006; Gropman et al., 2006; Madduri
et al., 2006). The reciprocal 3.7 Mb common microdupli-
cation syndrome dup(17)(p11.2p11.2) causes a milder
phenotype (Potocki et al., 2000). The recurrent rear-
rangements of 17p11.2 occur by meiotic NAHR (Shaw
et al., 2002; Bi et al., 2003) mediated by SMS-REP
LCRs (Chen et al., 1997; Park et al., 2002), whereas the
nonrecurrent rearrangements occur by both homolo-
gous (NAHR) and nonhomologous (NHEJ) mechanisms
(Shaw and Lupski, 2005).
Haploinsufficiency for the RAI1 and Rai1 (retinoic
acid-induced) genes which function in neuronal and or-
gan development in humans and mice, respectively
(Imai et al., 1995; Bi et al., 2005), is coupled with most
features of SMS (Bi et al., 2005; Girirajan et al., 2005);
RAI1 point mutations have been identified in SMS pa-
tients without deletion (Slager et al., 2003; Bi et al.,
2004; Girirajan et al., 2005; Bi and Lupski, 2006; Bi
et al., 2006). Patients with larger deletions have a more
severe phenotype (Madduri et al., 2006), including pe-
ripheral neuropathy, because these deletions extend
into the dosage-sensitive PMP22 gene that causes
HNPP when haploinsufficient (Trask et al., 1996). Ex-
periments in chromosome-engineered mouse models
for dup(17)(p11.2p11.2) syndrome (Walz et al., 2003,
Review
1072004), suggest that normal disomic Rai1 gene dosage is
sufficient to rescue the majority of complex physical and
behavioral phenotypes observed in Dp(11)17/+ mice
(Walz et al., 2006).
Neurofibromatosis Type 1 Mediated by Microdeletion
of 17q11.2
Recurrent interstitial microdeletions ofw1.5 Mb includ-
ing the NF1 tumor-suppressor gene are found in 5%–
20% of patients with autosomal dominant Neurofibro-
matosis type 1 (NF1; OMIM +162200) (Cnossen et al.,
1997; Rasmussen et al., 1998). NF1 is a highly variable
disorder; the signs and symptoms may begin at birth
and evolve over time and may be divided into tumor
(Theos and Korf, 2006) and nontumor manifestations.
The latter include variable deficits in cognition, learning
and memory, and attention (North et al., 1997; Zoller
et al., 1997). NF1 gene deletions produce a more severe
phenotype than point mutations (Leppig et al., 1997; De
Raedt et al., 2003), suggesting that complete loss of
gene function is more pathogenic and that dosage-sen-
sitive genes surrounding NF1 may influence ultimate
clinical outcome (i.e., by position effect or by physical
inclusion in the deletion).
This recurrent contiguous gene deletion (type I), which
encompasses NF1 and at least 13 other genes, occurs
via NAHR with rearrangement hot spots contained
within the NF1REP-P1 and NF1REP-M LCRs (Dorschner
et al., 2000; Jenne et al., 2001; Lo´pez-Correa et al., 2001;
Forbes et al., 2004). A smaller, recurrent, somatic micro-
deletion (type II) causing ‘‘segmental’’ NF1 accounts for
fewer (25%) NF1 microdeletions, which are mediated by
the JJAZ1 gene and JJAZ1pseudogene (J) during mito-
sis (Kehrer-Sawatzki et al., 2004).
Rearrangements of 22q with a Range of Cognitive
and Psychiatric Phenotypes
CNVs have also been found on chromosome 22, partic-
ularly on the q11 and q13 bands. Deletion of 22q11.2
causes DiGeorge (DGS; OMIM #188400)/velo-cardio-fa-
cial syndrome (VCFS; OMIM #192430), also referred to
as 22q11.2 deletion syndrome (22q11DS), while atypical
deletions (Rauch et al., 2005) distal to the commonly de-
leted region and duplication of 22q11.2 cause clinically
distinct syndromes. VCFS is associated with develop-
mental delay and a wide range of cognitive and neuro-
logical deficits, including that of speech, language,
memory, and attention (Lynch et al., 1995; Moss et al.,
1999; Bearden et al., 2001; Woodin et al., 2001; El Tahir
et al., 2004). Intriguingly, 15%–20% of individuals with
VCFS due to this 22q11.2 deletion were found to have
schizophrenia (Murphy and Owen, 2001; Murphy,
2002), suggesting that there may be a link between
genes in this region and psychiatric disorders.
The 3 Mb deletion causing VCFS contains the COMT
(catechol-O-methyltransferase; Shashi et al., 2006) and
TBX1 (T box transcription factor 1; Paylor et al., 2006)
genes. CNV of these genes has been implicated in the
cognitive and behavioral phenotypes associated with
VCFS. The breakpoints of the common recurrent dele-
tion are associated with three of the eight LCR22s found
in this region (Edelmann et al., 1999a; Shaikh et al., 2000)
and one particular Alu sequence (Uddin et al., 2006).
The clinical presentation of microduplication 22q11.2
syndrome (OMIM #608363) is highly variable, ranging
from extremely mildly affected individuals with behav-ioral abnormalities to individuals with multiple defects,
only some of which are similar to VCFS (Edelmann
et al., 1999b; Yobb et al., 2005). These duplications range
fromw3 Mb (common) tow4 Mb andw6 Mb within the
22q11.21–q11.23 chromosome region, and the break-
points also appear to be associated with LCR22s (Edel-
mann et al., 1999b; Ensenauer et al., 2003). One case of
triplication (i.e., resulting in four copies of this region)
has also been identified (Yobb et al., 2005). LCR22s
have also been shown to alter the dosage of 22q11 by
mediating (1) an (11;22) translocation causing the
der(22) syndrome and (2) the formation of a supernumer-
ary chromosome resulting in Cat-Eye syndrome (CES;
OMIM#115470; McDermid and Morrow, 2002).
Patients with 22q13 deletion syndrome, or Phelan-
McDermid Syndrome (OMIM #606232), present with
global developmental delay, hypotonia, absent or de-
layed speech, mental retardation, and normal to ad-
vanced growth, in addition to some autistic and minor
dysmorphic features (Phelan et al., 2001). The deletions,
ranging from 100 kb to 9 Mb, are mostly paternal in origin
(Anderlid et al., 2002; Luciani et al., 2003; Wilson et al.,
2003). CNV causing haploinsufficiency of the SHANK3/
PROSAP2 gene (Boeckers et al., 1999a, 1999b; Naisbitt
et al., 1999), which encodes for a structural protein of the
postsynaptic density, may be causative for the associ-
ated neurological symptoms (Wilson et al., 2003).
X Chromosome CNV and Neurodevelopmental
Disorders
CNVs on the X chromosome have also been found to be
responsible for several disease-causing traits, the ob-
served sex-differences of which may be due to X inacti-
vation in females and hemizygosity in males. Rett syn-
drome (RTT; OMIM #312750), which primarily affects
females, is caused most often by loss-of-function muta-
tions in the MECP2 (Methyl CpG binding protein 2) gene
on chromosome Xq28 (Amir et al., 1999), and less fre-
quently by genomic deletion (Ravn et al., 2005). Consis-
tent with a dosage-dependent role for MECP2, gains in
copy number for a region spanning MECP2 have been
reported in boys with severe mental retardation and pro-
gressive neurological symptoms (i.e., spasticity and
seizures; Meins et al., 2005; Van Esch et al., 2005; del
Gaudio et al., 2006). The MECP2-overexpression mouse
model gives a similar neurological phenotype (Collins
et al., 2004).
The sizes of the duplications range from 200 kb to
2.2 Mb, and five critical genes found within the minimal
duplication region reported include L1CAM through
MECP2 (Meins et al., 2005; Van Esch et al., 2005; del
Gaudio et al., 2006). The phenotypic severity appears
to correlate with increased MECP2 gene dosage rather
than with duplication size. A complex array of variously
oriented LCRs (LCR-MECP2s) are found scattered
throughout anw4 Mb region flanking MECP2, suggest-
ing the potential involvement of these LCRs in these rear-
rangements (Figure 2A; del Gaudio et al., 2006).
CNV of the PLP1 (proteolipid protein 1) locus is re-
sponsible for the dysmyelinating disorder Pelizaeus-
Merzbacher disease (PMD; OMIM #312080; Gencic
et al., 1989). X-linked recessive inheritance of nonrecur-
rent PLP1 gene duplications accounts for the majority of
PMD cases (60%–70%; Sistermans et al., 1998), while
most of the remaining cases are due to point mutations
Neuron
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Genomic Architecture in Regions of Nonre-
current Rearrangement Causing CNV
(A) Thew4 Mb surrounding the MECP2 gene
(pink circle) on the X chromosome, (B) the
w3 Mb surrounding the PLP1 gene (red
circle) on the X chromosome, and (C) the
w13 Mb surrounding the APP gene (green
circle) on chromosome 21 contain numerous
LCRs in various orientations. LCRs are repre-
sented by colored block arrows, and like-LCR
copies are designated by similar colors.
Orientation is depicted by the direction of
the block arrow, and the genomic regions
are shown centromeric (cen) to telomeric
(tel). Genomic positions are based on draft
Build 35.
A portion of this figure was obtained from Lee
et al. (2006a) by permission of Oxford Univer-
sity Press.and deletions. Genomic rearrangements causing a posi-
tion effect were also reported as a potential fourth muta-
tional mechanism (Muncke et al., 2004; Lee et al., 2006b).
PMD manifests as a spectrum of diseases affecting
the CNS, from severe early-onset encephalopathy due
to missense mutations, to a classic form which is pres-
ent in patients with PLP1 duplication, to a more mild
form which includes the PLP1 gene-deletion phenotype
characterized by peripheral and central neuropathy, and
the later-onset allelic disorder spastic paraplegia type 2
(SPG2; OMIM #312920; Johnston and Mc Kusick, 1962;
Saugier-Veber et al., 1994). Classic PMD patients gener-
ally present with nystagmus, spastic quadriplegia,
ataxia, and developmental and cognitive delay (Garbern
et al., 1999). A cellular trafficking defect arises from
dosage alteration ofPLP1, affecting disease pathogene-
sis and severity (Southwood and Gow, 2001).
While duplications and deletions of PLP1 are nonre-
current, most share a similar distal breakpoint near
LCR-PMDA and B (Inoue et al., 2002; Woodward
et al., 2005; Lee et al., 2006a), which are among a
multitude of LCR-PMDs in the w3 Mb region flanking
PLP1 (Figure 2B; Lee et al., 2006a). Thus far, CNV by
PLP1 duplication is consistent with a coupled homolo-
gous and nonhomologous mechanism (Woodward
et al., 2005; Lee et al., 2006a). Deletions are thought
to occur by submicroscopic X to autosome transloca-
tion, Alu-Alu recombination, and NHEJ (Inoue et al.,
2002).
On the long arm of the X chromosome (Xq26.3) is the
SOX3 (SRY-related HMG box 3) gene (Stevanovic et al.,
1993), which may be important for normal cognitive
function and language/speech development (Rousseau
et al., 1991; Laumonnier et al., 2002). Whereas the pre-
cise role of SOX3 in cognitive function is still somewhat
unclear (Woods et al., 2005), CNV of this gene may be
responsible for a speech disorder. Recently, a 7.5 Mb
duplication of Xq26.2–q27.1 encompassing or disrupt-
ing the SOX3 gene was reported in affected female fam-
ily members with short stature, dysmorphic features,
and speech defects with stuttering and dyslalia; hear-
ing impairment, seizure, and nystagmus were variable
(Stankiewicz et al., 2005).Neurodegenerative Disorders
Neurodegenerative disorders are generally caused by
mutations acting over a long period of time in nonre-
generating tissue. Thus, the course of these disorders
is a progressive and irreversible degeneration of the af-
fected neurons and glial cells with a later onset of clin-
ical manifestations. Neurodegenerative disorders affect
brain function and can be divided into two types: those
conditions causing problems with movement, and
those affecting memory/dementia. There are a number
of neurodegenerative diseases that can be caused by
genomic rearrangement, a few examples of which we
discuss below and summarize in Table 2.
SMN1 Gene Dosage and Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a common autosomal
recessive disorder characterized by degeneration of the
anterior horn cells of the spinal cord leading to weak-
ness/wasting of voluntary muscles. SMA is caused by
homozygous absence of the telomeric SMN1 (survival
motor neuron gene 1, or SMNT) gene on chromosome
5q13 (Lefebvre et al., 1995). SMA can be divided into
four types: SMA I (OMIM #253300) is the most severe,
including hypotonia; SMA II (OMIM #253550) is inter-
mediate; SMA III (OMIM #253400) is mild; SMA IV
(OMIM#271150) has an adult onset. All types are char-
acterized by varying degrees of proximal muscle weak-
ness inversely correlated with age of onset, and life ex-
pectancies are drastically shortened with increasing
disease severity. In approximately 95% of patients, ho-
mozygous functional absence of the SMN1 gene due to
deletion of exons 7 and 8 or gene conversion to centro-
meric SMN2 (SMNC, distinguishable from SMNT by one
critical nucleotide difference in exon 7), for which only
10% of transcripts are processed correctly to form
a product identical to SMN1, is pathogenic (Burghes,
1997). Interestingly, increased SMN2 copy-number
and gene conversion events are correlated with a milder,
later-onset clinical phenotype (Mazzei et al., 2004; Wirth
et al., 2006).
a-Synuclein Gene Dosage and Parkinson’s Disease
Parkinson’s disease (PD; OMIM #168600) is the second
most common neurodegenerative disease next to
Alzheimer’s disease (see below). Of the six causative
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Disorder OMIM Locus Rearrangement Size (Mb) Repeats Mech. Gene Neurologic Findings
PD #168600 4q21 dup 0.22–0.39 SNCA Bradykinesia, rigidity,
postural reflex impairment,
resting tremor
4q21 trip 1.61–2.04 SNCA Above, plus early autonomic
failure, cerebellar and
hippocampal signs
SMA #253300
#253550
#253400
#271150
5q13 del, gene
conversion
w0.006 SMN1,
SMN2
Hypotonia, proximal
muscle weakness,
inability to walk
ADLD %169500 5q23.2 dup 0.170–0.341 NHEJ LMNB1 CNS demyelination,
spasticity, abnormal
MRI, cerebellar ataxia
CMT1A #118220 17p12 dup w1.4 CMT1A-REPs NAHR PMP22 Reduced motor NCV,
absent muscle stretch
reflexes, limb and
muscle weakness
HNPP #162500 17p12 del w1.4 CMT1A-REPs NAHR PMP22 numbness, muscle
weakness/atrophy,
palsies, reduced motor
and sensory NCV, focally
thickened myelin sheath
AD #104300 21q21 dup 0.58–6.37 LCR-ADs APP CAA, NFT, amyloid plaques
mech, mechanism; dup, duplication; del, deletion; trip, triplication; ADLD, autosomal dominant leukodystrophy; MRI, magnetic resonance im-
aging; NCV, nerve-conduction velocity; CAA, cerebral amyloid angiopathy; NFT, neurofibrillary tangles; OMIM, http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=OMIM.genes that have been identified for familial PD, theSNCA
(a-synuclein) gene on chromosome 4q21 has been im-
plicated in the rare form of autosomal dominant PD (Pol-
ymeropoulos et al., 1997). In addition, variability within
the SNCA promoter is associated with an increased
risk of PD, again suggesting that dosage or proper ex-
pression of the gene is critical to function (Maraganore
et al., 2006). a-Synuclein is a small synaptic protein
found to be a major component of Lewy bodies (LBs)
and Lewy neurites, which are the pathologic hallmarks
of sporadic PD and dementia with LBs (DLB), and glial
cell cytoplasmic inclusions (Spillantini et al., 1997; Tu
et al., 1998). In fact, it has been proposed that familial
and sporadic PD may share common pathways (Nish-
ioka et al., 2006). a-Synuclein-overexpressing mice
have also been shown to recapitulate the PD phenotype
(Masliah et al., 2000).
Constitutional genomic gains in SNCA copy number
have been shown to be causative for PD, and it appears
that dosage of this gene plays a major role in disease
severity (Eriksen et al., 2005). In particular, triplication
of SNCA encompassing 1.61 to 2.04 Mb causes a severe
form of PD distinguished by early onset, severe disease
progression, early dementia, early autonomic failure,
cerebellar signs, variable LB disease, neuronal loss in
the hippocampus, and neurodegeneration beyond the
substantia nigra (Polymeropoulos et al., 1997; Singleton
et al., 2003; Farrer et al., 2004). However, the phenotype
associated with SNCA duplications (w220 to 394 kb) is
consistent with late-onset idiopathic PD without the
atypical features seen with triplication (Chartier-Harlin
et al., 2004; Iba´n˜ez et al., 2004; Nishioka et al., 2006).
Thus, SNCA copy number and a-synuclein protein level
regulation appear to be significant factors contributing
to PD phenotypes. It has also been proposed that thesize of the genomic copy-number gain may also influ-
ence the phenotype (Nishioka et al., 2006).
Amyloid Precursor Protein Gene Dosage
and Alzheimer’s Disease
Germline duplication of the b amyloid locus APP (amy-
loid precursor protein) on chromosome 21q21 causes
autosomal dominant early-onset Alzheimer’s disease
(ADEOAD; AD, OMIM #104300) associated with heredi-
tary dementia and cerebral amyloid angiopathy (CAA)
with a frequency of 8% (Rovelet-Lecrux et al., 2006).
AD is characterized by intracellular neurofibrillary tan-
gles (NFT) and extracellular amyloid plaques that accu-
mulate in the brain (Sennvik et al., 2000). It has been sug-
gested that overexpression of APP peptides may
promote plaque accumulation by shifting the Ab42/
Ab40 ratio (Cabrejo et al., 2006). Additionally, mutations
in the APP promoter resulting in a neuron-specific in-
crease in APP expression have been associated with
AD (Theuns et al., 2006). ADEOAD with CAA is also found
in individuals with Down’s syndrome (DS; OMIM
#190685), who are at risk to develop the neuropatho-
logic features of AD with an early onset, supporting the
concept that gene dosage for this locus is causative of
AD. In a trisomic mouse model of DS, increased App ex-
pression was found to disrupt nerve growth factor (NGF)
transport and cause degeneration of cholinergic neu-
rons (Salehi et al., 2006).
Nonrecurrent APP genomic duplications were re-
ported to range in size from 580 kb to 6.37 Mb (Rove-
let-Lecrux et al., 2006), and in our independent analysis
of a 13 Mb genomic region surrounding the APP locus,
including PRSS7 through GRIK1 genes, a few LCRs
(LCR-ADs) are present (Figure 2C). These LCRs could
potentially stimulate rearrangements found in these
Alzheimer’s patients in a manner similar to what has
Neuron
110Figure 3. Subtle Changes in PMP22 Gene
Copy Number Affect CMT1A/HNPP Pheno-
type and Disease Severity
DNA in the left panel is denoted by solid black
lines, and parentheses designate a genomic
interval containing a dosage-sensitive gene
(square). A wild-type allele is designated as
‘‘+’’. Gain-of-function (GOF) mutations can
be caused by duplication (dup) or point muta-
tion (blue asterisk). Loss-of-function (LOF)
mutations can be caused by deletion (del) or
point mutation (red asterisk). The number of
PMP22 gene copies is shown for each geno-
type, as well as the corresponding pheno-
type. An example given for a LOF mutation
is T118M.been demonstrated for PLP1 duplication (Lee et al.,
2006a) and proposed for MECP2 duplication and tripli-
cation (del Gaudio et al., 2006). Furthermore, diagnostic
detection of APP CNV, as well as SNCA CNV, may be of
great predictive value.
Chromosome 17p12 CNV and Peripheral Neuropathy
Charcot-Marie-Tooth disease type 1A (CMT1A; OMIM
#118220) and hereditary neuropathy with liability to
pressure palsies (HNPP; OMIM #162500) are examples
of dysmyelinating autosomal dominant genomic disor-
ders which are caused by heterozygous duplication
and reciprocal deletion, respectively, of an w1.4 Mb
fragment, causing altered copy number of the dosage-
sensitive PMP22 (peripheral myelin protein 22) gene on
chromosome 17p12.
CMT is the most common inherited disorder of the
PNS (Skre, 1974), and patients with CMT1 exhibit sym-
metric, moderately to severely reduced motor nerve
conduction velocities with absent muscle stretch re-
flexes (Kaku et al., 1993). Clinical symptoms usually
present in the first or second decade of life, including
progressive weakness of distal limb muscles, causing a
characteristic gait abnormality, and hand muscle weak-
ness which occurs late in the disease progression
(Garcia, 1995). HNPP is a clinically distinct, rare, slowly
progressive neuromuscular disorder characterized by
recurrent acute peripheral nerve palsies (Windebank,
1993; Chance and Dyck, 1998; Pareyson et al., 1998;
Andersson et al., 2000; Li et al., 2004). Patients with
HNPP have periodic episodes of numbness, muscle
weakness, and muscle atrophy due to demyelination,
and variable palsies or peripheral nerve trauma (Earl
et al., 1964).
CMT1A is caused by duplication of thePMP22 locus in
70% of CMT1 patients. Meiotic NAHR mediated byCMT1A-REP LCRs causes PMP22 CNV (Pentao et al.,
1992; Chance et al., 1994; Reiter et al., 1997, 1998).
The first NAHR recombination hot spot was identified
within CMT1A-REP (Reiter et al., 1996), and recent anal-
ysis of sequence variation at CMT1A-REPs revealed that
an allelic homologous recombination (AHR) hot spot was
coincident with an NAHR hot spot (Lindsay et al., 2006).
The human genome is punctuated by recombination hot
spots and cold spots; however, the physical basis of
both NAHR and AHR hot spots remains to be elucidated
(Lupski, 2004). Depending on if there are too many or too
few copies of PMP22, CNV of this single gene causes
very different phenotypes, likely through its affect on
Schwann cell proliferation (Hanemann et al., 1998). Con-
sistent with the dosage hypothesis, patients with homo-
zygous duplication generally manifest a more severe
phenotype (Lupski et al., 1991; Kaku et al., 1993).
Subtle dosage changes depending on the combina-
tion of gain-of-function and loss-of-function alleles of
PMP22 can result in a spectrum of dosage-related phe-
notypes (Figure 3). For example, whereas heterozygous
duplication of PMP22 causes CMT1A, homozygous du-
plication causes a more severe CMT1A phenotype.
PMP22 gain-of-function point mutations can also cause
CMT1A (Valentijn et al., 1992; Roa et al., 1993), whereas
frameshift or nonsense alleles cause HNPP consistent
with a haploinsufficiency disease. Interestingly, the par-
tial loss-of-function T118M PMP22 mutation can not
only mitigate the effects of PMP22 duplication, but it
can also result in an HNPP phenotype when paired
with a normal allele (Shy et al., 2006; Figure 3).
As in the case for CMT1A, another-adult onset neuro-
logic disease, autosomal dominant leukodystrophy
(ADLD; OMIM %169500), has been shown recently to
result from genomic duplication of a dosage-sensitive
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111gene, LMNB1 (Lamin B1), critical to maintenance of the
nervous system (Padiath et al., 2006; Table 2).
Psychiatric Disorders
Psychiatric/psychological disorders are to some degree
influenced by both genetic and environmental factors.
These conditions include mental illnesses characterized
by the impairment of an individual’s normal cognitive,
emotional, or behavioral functioning. They are challeng-
ing to ascertain and treat clinically because of the intri-
cate nature of human behavior, and they are problematic
for researchers because of genetic heterogeneity, in-
complete penetrance of psychiatric traits, and non-
Mendelian inheritance of complex traits. The genetics
and genomics of behavioral and psychiatric disorders
has been reviewed recently (Inoue and Lupski, 2003).
While genome-wide association studies have drawn at-
tention to certain chromosome regions with respect to
psychiatric disease, progress has been limited in terms
of identifying disease-associated alleles prevalent in
the general population. Conversely, rare individuals or
families with psychiatric disease who are found to
have cytogenetic rearrangements can potentially reveal
disease-associated loci (Millar et al., 2000, 2005; Kam-
nasaran et al., 2003). Below, we discuss several
instances in which psychiatric disorders are found to
be associated with genomic rearrangements, suggest-
ing that copy number of still-undetermined dosage-
sensitive genes is altered (Table 3).
Chromosome 4 has proven to be a good candidate for
mood disorders and affective disturbances in several in-
dependent studies (Fullerton et al., 2003; Middleton
et al., 2004; Ramanathan et al., 2004). Recently, a rare
case of de novo maternal uniparental isodisomy of chro-
mosome 4 (UPD4) was reported in which the female pro-
band had a mild phenotype characterized by major
depressive disorder (MDD) associated with suicide
attempts (Middleton et al., 2006). This is the third re-
ported case of UPD4 (Lindenbaum et al., 1991; Spena
et al., 2004) but the first case associated with a mood
disorder. Since one of the other reported cases also in-
volved maternal UPD, it is likely that the UPD4 in this
proband is causative for her MDD, through a mechanism
of homozygosity for a maternal recessive allele.
Genome-wide scans have revealed strong linkage for
a causative gene for bipolar disorder to a distal region of
chromosome 8q (Cichon et al., 2001; Dick et al., 2003;
Liu et al., 2003; McInnis et al., 2003; Avramopoulos
et al., 2004; McQueen et al., 2005). Interestingly, a single
case study reported a male patient with bipolar disorder
and speech delay who was found to have duplication of
Table 3. Psychiatric Disorders Caused by Genomic
Rearrangements and Gene Copy-Number Variation
Locus Rearrangement Psychiatric Phenotype
Chromosome 4 UPD4 Major depressive disorder
8q22.1–q24.1 dup Bipolar disorder, speech
delay, ADHD, aggression
15q14/pter dup Bipolar disorder, dysmorphism,
hypotonia
15q24–q26 dup Panic and phobic disorders
UPD, uniparental disomy; dup, duplication; ADHD, attention-deficit
hyperactivity disorder.8q22.1–q24.1 due to an unbalanced translocation and
partial trisomy of 8q (Macayran et al., 2006). The pa-
tient’s phenotype includes ADHD, impulsivity, pres-
sured speech, delayed language, sleep disturbance, ag-
gression, and hypersexuality; neurological examination
was normal but deficits in fine motor and social skills
were noted, as well as an unconfirmed family history of
mood disorders (Macayran et al., 2006). Partial chromo-
some 8q trisomy, potentially including dosage-sensitive
genes important for normal brain function, may be re-
sponsible for the patient’s psychiatric phenotype (Mac-
ayran et al., 2006).
Another informative patient with bipolar affective dis-
order and duplication of chromosome 15q14/pter, and
thus partial trisomy 15, has been followed longitudinally
for over 15 years (Reif et al., 2004). This patient also pres-
ents with dysmorphic features, positive pyramidal tract
signs, hypotonia, awkward movements, and intellectual
impairment (Reif et al., 2004). Interestingly, trisomy 15
mosaicism is known to cause a PWS phenotype, which
is often characterized by cycloid psychosis and bipolar
affective disorder (Liu et al., 2001). The abnormal expres-
sion of an imprinted gene underlying psychotic illness in
PWS possibly may account for the bipolar phenotype in
duplication 15q14/pter, or this rearrangement could
represent a distinct clinical entity. Intriguingly, chromo-
some 15q13–q15 has been implicated independently
as a susceptibility locus for schizophrenia (Sto¨ber
et al., 2000; Liu et al., 2001), and in Andermann’s syn-
drome, which is associated with progressive peripheral
neuropathy, agenesis of the corpus callosum, and
some psychotic features (Casaubon et al., 1996).
Whether there is a genomic susceptibility factor for
panic and phobic disorders on chromosome 15 is a sub-
ject of debate. An interstitial duplication of chromosome
15q24–q26 was identified as a polymorphism in a study
population, and this CNV (DUP25) was found to be sig-
nificantly associated with panic/agoraphobia/social
phobia/joint laxity and panic disorder (Grataco`s et al.,
2001). Grataco`s et al. identified two different types of
DUP25 by fluorescence in situ hybridization (FISH) in
72% of patients with panic disorder tested, but with in-
complete penetrance (80%), whereas the frequency of
DUP25 in the general population was found to be 7%
(Grataco`s et al., 2001). Flanking the DUP25 region are
LCR15 sequences (Pujana et al., 2001) which may medi-
ate the duplication, a rearrangement which is proposed
to be mitotic in origin and inherited in a non-Mendelian
fashion (Grataco`s et al., 2001). However, several inde-
pendent investigators have not been able to detect
DUP25 in the same and other cohorts of anxiety-disor-
der patients and have thus been unable to confirm an as-
sociation between DUP25 and anxiety disorders (Hollox
and Armour, 2003; Schumacher et al., 2003; Tabiner
et al., 2003; Weiland et al., 2003; Henrichsen et al.,
2004; Vermeulen et al., 2004; Zhu et al., 2004).
Copy-Number Variation in the General Population
CNV is unexpectedly prevalent in the genomes of normal
individuals in population-based studies (Iafrate et al.,
2004; Sebat et al., 2004; Rendon et al., 2006), with a cu-
mulative total of 1296 CNVs covering approximately 143
Mb of sequence (http://projects.tcag.ca/variation; Free-
man et al., 2006). These CNVs appear for the most part
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112to be heritable with only modest linkage disequilibrium
(LD) with SNPs (Locke et al., 2006). This modest LD
may be due to (1) poor SNP coverage in complex re-
gions, (2) high error rate for genotyping CNVs, (3) high re-
combination rate in regions of CNV, or (4) high rate of
spontaneous recurrence of CNVs. CNV has been found
to account for a substantial amount of genetic variation
between individuals, and it may account for a significant
portion of normal phenotypic variation (Freeman et al.,
2006), such as normal behavioral differences or an indi-
vidual’s disease susceptibility (Nadeau and Lee, 2006).
Furthermore, CNV is not confined to a single population
group, indicating that either these variants were present
early in human history, or that they are highly recurrent
events (Sharp et al., 2005). Because of the prevalence
of CNV in the human population, the concept of a ‘‘nor-
mal copy number’’ of a given gene or genomic region
has thus, in some cases, become unclear (Axton, 2006).
Duplications and deletions affecting the copy number
of certain genes may often act as benign euchromatic
variants (i.e., without phenotypic effect; Barber et al.,
1998; Engelen et al., 2000). However, CNV of dosage-
sensitive genes which have a function(s) in the nervous
system, such as PMP22, PLP1, RAI1, and others dis-
cussed herein, have direct clinical outcomes which
may present early-on or may act over a long period of
time through a multitude of mechanisms (i.e., protein
trafficking or accumulation, neuronal differentiation,
etc.). Thus, in addition to single-nucleotide and cod-
ing-region changes, alteration of gene copy number or
dosage and expression may produce phenotypic ef-
fects. Aside from CNV, other proposed molecular mech-
anisms by which genomic rearrangements can poten-
tially alter gene dosage and expression and thereby
convey a phenotype include gene interruption, gene
fusion, position effect, unmasking a recessive allele
or functional polymorphism, and possibly disruption
in regulatory interactions between chromosomes by a
transvection effect (Lupski and Stankiewicz, 2005).
Copy-Number Variation and Higher-Order Genomic
Architecture
Higher-order genomic features have been suggested to
function in mediating (or stimulating) normal variation in
the human genome. Using array comparative genomic
hybridization (CGH) technology to assess CNV in puta-
tive rearrangement-hot spot regions flanked by a certain
subclass of LCRs in the normal population, a 4- to 5-fold
enrichment of CNV was observed compared to control
regions (Sharp et al., 2005), similar to the high number
of SNPs previously reported within LCRs (Bailey et al.,
2002), such as CMT1A-REP (Estivill et al., 2002; Lindsay
et al., 2006). Furthermore, Sharp et al. found an enrich-
ment of rearrangement-hot spot sequences within the
more frequently occurring CNVs. Accordingly, a strong
link has been established between higher-order geno-
mic architecture and CNV in the human genome (Iafrate
et al., 2004; Sebat et al., 2004). CNV has been identified
in regions which are generally not gene poor (Sharp
et al., 2005) and may include genes for which dosage
is critical. Thus, LCRs may play an important role both
in normal structural variation and in CNV causing geno-
mic disorders.Copy-Number Variation and Complex Traits
Some of the neurologic disorders discussed above are
single-gene disorders, but many are single-locus CGS,
including WBS, PWS, and 22q11DS, to name a few. Sev-
eral of these disorders present with distinct behavioral,
psychological, and physical phenotypes. The existence
of these complex characteristic traits observed in indi-
viduals with particular genomic rearrangements lends
support to the concept that these traits are to some ex-
tent genetically determined. Thus, structural genomic
changes, or CNV of a gene(s) contained within the re-
arranged segment, may be directly responsible for the
associated phenotype. It is not a major leap to hypoth-
esize that other CNVs could account for behavioral or
psychological variations among individuals in the gen-
eral population.
The partial overlap in the disease traits observed for
the selected neurologic disorders discussed herein
can be appreciated. For example, some common fea-
tures include developmental delay, cognitive and visuo-
spatial construction deficits, autistic features, hypoto-
nia, and dysmorphic features, among others. While the
complex traits associated with some genomic disorders
may be a general property of higher-level changes in
brain architecture or neuronal connections that could
be common to a number of disparate deletion or dupli-
cation syndromes, others may be assigned to one spe-
cific gene. And while susceptibility to HIV, lupus with
glomerulonephritis, and Crohn’s disease has recently
been linked to CNV of CCL3L1, FCGR3B, and HBD-2
genes, respectively (Gonzalez et al., 2005; Aitman
et al., 2006; Fellermann et al., 2006), there are many con-
ditions and CGS disorders for which the causative
gene(s) has not yet been determined. Future studies of
CNV in relation to complex human genetic disease traits
will bring us toward the identification of specific dosage-
sensitive genes important for neurocognitive skills/
deficits, personality determinants, behavioral abnormal-
ities, and psychiatric disorders. CNV can now be consid-
ered, along with single-nucleotide and coding-region
changes, as an important factor contributing to human
variation, disease, and complex traits.
Heritability of Behavioral and Personality Traits
Not only have constitutional (as opposed to somatic)
CNVs been found to be heritable, but behavioral, per-
sonality, and psychiatric traits themselves have been
found to potentially have a large genetic component
(Tellegen et al., 1988; Plomin, 1990; Bouchard, 1994;
McGue and Bouchard, 1998). In fact, genetic factors
may account for at least half of the variability in person-
ality (Tellegen et al., 1988). In studies measuring the con-
cordance between monozygotic (MZ) versus dizygotic
(DZ) twins, the results were approximately 2-fold higher
for MZ twins for most behavioral disorders (McGue and
Bouchard, 1998). It is possible that almost all individual
psychological differences are substantially heritable
(Bouchard and McGue, 2003). From studies of identical
twins reared together versus apart, it was concluded
that human behavior has little influence from a shared
environment (Tellegen et al., 1988), except perhaps for
cognitive ability, juvenile delinquency, and antisocial be-
havior traits (Chipeur et al., 1990; Bouchard and McGue,
2003). In general, the only significant environmental
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ment (McGue and Bouchard, 1998), but this influence
is likely far overshadowed by the substantial genetic
factor.
The concept of population-specific behaviors has
gotten some recent attention. It was found that based
on a five-factor model (McCrae and John, 1992), individ-
uals believe that members of their respective cultures
globally possess certain personality traits more than
others. It was determined by extensive objective testing
that while their aggregate descriptions of cultural per-
ceptions revealed distinct personality differences
across cultures, these differences did not reveal a cul-
ture-specific personality profile and argued against
any evidence for a national stereotype (McCrae and Ter-
racciano, 2005; Terracciano et al., 2005). However, while
the validity of national stereotypes may be in doubt, se-
lected populations scored differently on these tests
(Terracciano et al., 2005), and the fact remains that per-
sonality, behavior, and psychiatric traits are largely her-
itable. These traits often result from the contribution of
many genes, lending to the complexity of human behav-
ior. The molecular bases of such behavioral traits remain
to be determined, but CNV and gene-dosage effects
are distinct possibilities. Heritable population-specific
CNVs could potentially underlie some behavioral ten-
dencies of selected world populations.
Animal Studies Suggest CNV of Select Genes Can
Cause Complex Traits, Including Behavior
Experiments in chromosome-engineered mouse models
demonstrate that CNV of just a single gene can be re-
sponsible for the majority of complex behavioral and
physical disease traits. Using an established mouse
model for dup(17)(p11.2p11.2) syndrome, or Dp(11)17/+
(Walz et al., 2003, 2004), that recapitulates most of the
phenotypes in human patients, Walz et al. (2006) attemp-
ted to explore the role of Rai1 copy number in the
Dp(11)17/+ phenotype. When Dp(11)17/+ and Df(11)17/+
mice were mated, the physical and behavioral traits of
Dp(11)17/Df(11)17 progeny, in which the dosage of all
19 genes in the SMS critical interval is balanced, were
normalized (Figure 4). Additionally, Rai1+/2 mice were
generated that had a phenotype similar to that of
Df(11)17/+ animals (Bi et al., 2005), even though they
were haploinsufficient for only one of the 19 SMS critical
interval genes deleted in the Df(11)17/+ chromosome-
engineered model (Figure 4). In the generation of
Dp(11)17/Rai12 compound heterozygous animals, it
was determined that restoring the copy number of Rai1
alone is sufficient to rescue the duplication phenotype,
despite the trisomic copy number of the remaining 18
genes in the SMS critical interval (Figure 4). Thus, nor-
malizing the copy number of just a single gene is suffi-
cient to rescue the majority of complex physical and
behavioral phenotypes (Walz et al., 2006).
Treatment of Disorders Due to Gene Dosage
If a genomic disorder results from altered gene dosage,
it may be possible to intervene therapeutically by cor-
recting the gene dosage. Recent therapeutic strategies
to treat disorders caused by CNV have been aimed at
correcting gene dosage epigenetically, as opposed to
physical genetic modification of the causative gene. Assteroid hormones have long been known to stimulate
myelination in peripheral nerves, and since PMP22 ex-
pression is regulated by steroids, Sereda et al. (2003)
postulated that modulation of gene expression could
be achieved through hormone therapy. In a Pmp22-
overexpressing rat model of CMT1A, daily administra-
tion of progesterone elevates the levels of Pmp22
mRNA and Pmp22 protein and exacerbates the clinical
neuropathy, whereas onapristone, a selective proges-
terone receptor antagonist, reduces Pmp22 overex-
pression and improves the CMT phenotype (Sereda
et al., 2003). Likewise, Passage et al. (2004) attempted
to ameliorate the demyelinating CMT phenotype in a
mouse model of CMT1A through the administration of
ascorbic acid, a known promoter of myelination. Ascor-
bic acid treatment effectively reduced Pmp22 expres-
sion and either halted neurologic deterioration or im-
proved motor performance (Passage et al., 2004).
Accordingly, future treatments aimed at epigenetically
Figure 4. Rai1 (Retinoic Acid-Induced) Is the Single Gene Responsi-
ble for the Physical and Behavioral Phenotypes Associated with
dup(17)(p11.2p11.2)
(A) Breeding schemes are shown, and the associated phenotypes
(boxes) for the Df(11)17/+, Dp(11)17/+, and Rai1+/2 mice involved
in the generation of Dp(11)17/Df(11)17 and Dp(11)17/Rai12 mice,
whose rescue phenotypes are similar.
(B) SMS critical region contains 19 genes, including Rai1 (open cir-
cle). Dosage ofRai1 and of the other 18 critical-region genes exclud-
ingRai1 for each of the mouse genotypes detailed in (A) is displayed.
Each ‘‘+’’ represents one genomic copy. ‘‘LMD’’ refers to learning
and memory deficit, ‘‘Dp’’ to duplication, and ‘‘Df’’ to deficiency.
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114correcting gene dosage or the downstream processes
affected by such altered gene dosage in individuals
with disease-associated CNV may prove beneficial.
High-Resolution Genome Analysis of CNV
During the last two decades, technology developments
have enabled a higher-resolution analysis of the human
genome, not only for research purposes but also in clin-
ical diagnostic testing for disease-causing CNVs. The
diagnosis of genomic rearrangements has seen a shift
from cytogenetic techniques such as G-banding to mo-
lecular techniques including locus-specific FISH, chro-
mosome painting (Schrock et al., 2006), and telomere
FISH (Flint and Knight, 2003). Pulsed-field gel electro-
phoresis (PFGE), used to detect a rearrangement-spe-
cific junction fragment for common rearrangements
within a size range (>25 kb and <5 Mb) not detectable
by previous technologies, is now considered time- and
labor-intensive compared with new technologies. Re-
cently, array CGH using BAC and PAC genomic clones
as well as multiple oligonucleotide array platforms
have been successfully used to identify genomic dele-
tions and duplications (Bruder et al., 2001; Veltman
et al., 2003; Sebat et al., 2004; Shaw et al., 2004a;
Cheung et al., 2005; Lee et al., 2005; Ming et al., 2006;
Rendon et al., 2006; Wirtenberger et al., 2006). This tech-
nology enables a higher throughput than FISH and PFGE
and may be especially useful in identifying new genomic
disorders or in detecting submicroscopic rearrange-
ments not visible by routine chromosome analysis (Viss-
ers et al., 2003). Both genome-wide tiling resolution ar-
rays and targeted arrays designed using an informed
approach based on NAHR mechanisms have recently
enabled the identification of new genomic disorders as-
sociated with recurrent rearrangements (Koolen et al.,
2006; Sharp et al., 2006; Shaw-Smith et al., 2006). Tar-
geted quantitative real-time and semiquantitative PCR
and multiplex ligation-dependent probe amplification
(MLPA) methodologies following array CGH have also
proven useful for higher-resolution mapping of regions
of CNV (Koolen et al., 2006; Lee et al., 2006b; Wilson
et al., 2006). Based on our current understanding of ge-
nome architecture and susceptibility to nonrecurrent
DNA rearrangements (Figure 2), targeted arrays could
potentially be designed to identify regions of CNV
flanked by LCRs that likely stimulate rearrangement
through a mechanism of NHEJ instead of NAHR.
Summary
Neurodevelopmental and neurodegenerative disorders
can be caused by LCR-mediated/stimulated genomic
rearrangements resulting in altered gene dosage or
CNV. Psychiatric disorders, including mood and anxiety
disorders, have also been associated with genomic re-
arrangements. These rearrangements result in the al-
tered copy number, either too many or too few, of a dos-
age-sensitive gene(s) contained within the rearranged
genomic interval. Such structural alterations to the ge-
nome, as opposed to single-nucleotide or coding-region
changes, can clearly result in a variety of neurologic
conditions and specific yet complex behavioral traits,
either due to CNV of a contiguous set of genes or from
CNV of just a single gene that has some function in the
nervous system. To further dissect these structuralchanges, while duplication or deletion size sometimes
lends severity to the clinical phenotype (i.e., PMD and
SMS), additional genomic gains or gene copy numbers
(i.e., PMP22 homozygous duplications, SNCA and
MECP2 triplications) often contribute more to disease
severity than does the rearrangement size. As is the
case for SMS and the reciprocal dup(17)(p11.2p11.2)
syndrome and the mouse models for these conditions,
it is possible that the majority of physical and behavioral
signs associated with other contiguous gene neurologi-
cal and behavioral phenotypes could instead be due to
CNV of only a single gene.
When a genomic rearrangement is common, recur-
rent, and has clustered breakpoints, NAHR mediated
by region-specific LCRs is the prevailing mechanism.
Nonclustered rearrangement breakpoints have been
observed for nonrecurrent rearrangements; however,
they can be mediated by homologous or nonhomolo-
gous (NHEJ) mechanisms. Whereas the rules for
NAHR-driven recurrent genomic rearrangements have
begun to be understood, the molecular mechanisms
for nonrecurrent rearrangements remain rudimentary.
Regarding the rearrangements resulting in CNV and
causing the neurodevelopmental and neurodegenera-
tive diseases discussed herein, the majority of rear-
rangement breakpoints are found to be in the vicinity
of LCRs or other repeated genic sequences. An associ-
ation has in fact been established between LCRs and re-
gions of CNV. However, direct experimental evidence by
sequencing the products of recombination at the break-
points remains to be established for CNV. Aside from the
widespread CNV found throughout the genomes of nor-
mal individuals (i.e., normal structural variation), CNV of
dosage-sensitive genes, in this case those that serve
a function in the nervous system, results in a variety of
genomic disorders. Complete LCR and breakpoint anal-
yses for the remainder of neurologic disorders for which
such analyses have not yet been performed could prove
very informative for determining the molecular mecha-
nisms for their associated genomic rearrangements re-
sulting in CNV.
Because of the surprisingly high level of CNV found in
the normal population, genomic rearrangements medi-
ated or stimulated by LCRs or other repeated genic se-
quences and the resulting CNV of a single gene or mul-
tiple genes important for nervous system function may
potentially account for a higher proportion of heritable
neurologic and psychiatric traits than is currently
realized.
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